{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:12 23:20:22.323",
            "Expression": "mesenchymal allo-APZ2-CVU",
            "NStudiesAvail": 430639,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Wound size change in percent at each post-baseline follow-up visit will be evaluated.",
                              "Time to complete wound closure will be evaluated.",
                              "Complete wound closures at each post-baseline follow-up visit will be evaluated.",
                              "Duration of wound closure will be evaluated.",
                              "Recurrence of the wound will be evaluated.",
                              "The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the amount and type of wound exudate.",
                              "The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the formation of granulation tissue together with epithelialization.",
                              "The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the questions regarding scar formation.",
                              "Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14 will be evaluated.",
                              "Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit will be evaluated.",
                              "A physical body examination (e.g. general appearance, thyroid, head, lungs and thorax, ears, cardiovascular system, eyes, abdomen, nose-mouth-throat, musculoskeletal system, skin, extremities, lymph nodes, neurological system) will be performed and abnormal physical examination results will be evaluated and reported as AEs."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Wound size change in percent at each post-baseline follow-up visit",
                              "Time to complete wound closure",
                              "Complete wound closures at each post-baseline follow-up visit",
                              "Duration of wound closure",
                              "Recurrence of the wound",
                              "Quality of wound healing (wound exudate) at each post-baseline follow-up visit",
                              "Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit",
                              "Quality of wound healing (scar formation) at each post-baseline follow-up visit",
                              "Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14",
                              "Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit",
                              "Physical examination and vital signs at V14"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Week 6, 12, 18",
                              "Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10",
                              "Week 18"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04971161"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Percentage of wound size reduction",
                              "Absolute wound size reduction",
                              "Proportion of patients achieving complete wound closure",
                              "Time to first complete wound closure",
                              "Proportion of patients achieving 30% wound closure",
                              "Time to first 30% wound closure",
                              "Epithelialization",
                              "Assessment of further wound healing parameters: formation of granulation tissue and wound exudation",
                              "Pain assessment as per numerical rating scale (NRS)",
                              "Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire",
                              "Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire",
                              "Physical examination and vital signs at Week 6.1 and Week 12"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12 (without LOCF);",
                              "Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12",
                              "Weeks 2, 3, 4, 6, 8, 10, 12, and at any time point",
                              "A priori specification not possible; between baseline and week 12 post baseline",
                              "Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, 12, and at any time point",
                              "A priori specification not possible; between baseline and week 12 post baseline",
                              "Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12",
                              "Visit 3 and Visit 10 before IMP application, Days 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.2, 8, 10, and 12",
                              "Days 0, 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12",
                              "Day 0 and Weeks 4, 8 and 12",
                              "Day 0 and Weeks 4, 8 and 12",
                              "Week 6.1 and Week 12"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03257098"
                        ]
                  }
            ]
      }
}